This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionLast revisionBoth sides next revision | ||
home:othertreatments:antitnf [11.02.2009] – marysue | home:othertreatments:antitnf [08.26.2017] – [Increased risk of infection] sallieq | ||
---|---|---|---|
Line 1: | Line 1: | ||
====== Anti-TNF drugs ====== | ====== Anti-TNF drugs ====== | ||
- | <html>< | + | <relatedarticle> [[home: |
Line 7: | Line 7: | ||
Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance and is required for proper proliferation and function of natural killer cells, T cells, B cells, macrophages, | Tumor necrosis factor-alpha or TNF-alpha is a cytokine critical for effective immune surveillance and is required for proper proliferation and function of natural killer cells, T cells, B cells, macrophages, | ||
- | Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects. | + | Anti-TNF drugs are expensive, ineffective at treating chronic disease and have a number of adverse effects. |
- | + | ||
- | Anti-TNF drugs can make a patient feel temporarily less symptomatic, | + | |
Line 30: | Line 28: | ||
==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== | ==== Olmesartan (Benicar) vs. TNF-alpha blockers ==== | ||
- | <html>< | + | <relatedarticle> [[home: |
Line 51: | Line 49: | ||
- | [[http:// | + | [[https://google2.fda.gov/ |
< | < | ||
- | //**U.S. Food and Drug Administration**//, | + | //**U.S. Food and Drug Administration**//, |
//M. tuberculosis// | //M. tuberculosis// | ||
Line 65: | Line 63: | ||
To reduce the likelihood of contracting or exacerbating tuberculosis, | To reduce the likelihood of contracting or exacerbating tuberculosis, | ||
- | Fatal fungal | + | " |
Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. | Researchers have also observed reactivation of latent viral infections, namely hepatitis B in patients who are chronic carriers of the virus. | ||
Line 77: | Line 75: | ||
* **Liver problems** – [[http:// | * **Liver problems** – [[http:// | ||
* **Skin problems** – In one prospective trial, 25% of patients on TNF-alpha-blocking therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time.(({{pubmed> | * **Skin problems** – In one prospective trial, 25% of patients on TNF-alpha-blocking therapy suffered from a dermatological condition that led them to visit a skin specialist. In a control group of patients who were not undergoing TNF-alpha blocking therapy and had less severe disease only 13% visited a dermatologist during the same period of time.(({{pubmed> | ||
- | * **Cancer** – One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 3.3 times higher risk for " | + | * **Cancer** – One recent systematic review of the adverse effects of anti-TNF therapies as they were used in rheumatoid arthritis concluded that patients taking the drugs are at 3.3 times higher risk for " |
Line 99: | Line 97: | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||
- | EDIT | + | |
* Legacy content | * Legacy content | ||
* http:// | * http:// | ||
===== References ===== | ===== References ===== |